# OnCo record gatekeeper-mutation (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/gatekeeper-mutation/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "gatekeeper-mutation" ;
  schema:name "On-target resistance mutations (gatekeeper, solvent-front, compound)"@en ;
  schema:alternateName "gatekeeper"@en, "gatekeeper mutation"@en, "solvent-front mutation"@en, "solvent front"@en, "compound mutations"@en, "compound mutation"@en, "G1202R"@en, "G2032R"@en, "on-target resistance"@en, "secondary mutation"@en, "resistance mutation"@en, "acquired resistance mutation"@en, "kinase domain mutation"@en, "resistance mutations"@en, "gatekeeper mutations"@en, "secondary mutations"@en, "solvent-front mutations"@en ;
  schema:description "When a cancer becomes resistant to a targeted pill, it often does so by changing the exact spot where the drug binds: a 'gatekeeper' or 'solvent-front' mutation. Next-generation drugs are designed to fit around these changes."@en ;
  schema:url <https://onco.cc/terms/gatekeeper-mutation/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Drug_resistance> ;
  schema:citation <https://en.wikipedia.org/wiki/Drug_resistance> ;
  onco:related <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/egfr-mutation-subtypes/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/cfdna/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ros1/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/> .